A COMPREHENSIVE COMPENDIUM ON DRUG THERAPY covering all prescription drugs and selected over-the-counter drugs will be published under the aegis of The Food and Drug Administration and distributed free to pharmacists, hospitals, physicians and others. authorized to prescribe drugs within the next two or three years.
Plans for the new Drug Compendium are being spear-headed by Duke .C. Trexler, Executive Director of the Drug Research Board's Drug Efficacy Study, National Research Council-National Academy of Sciences, who is directing the study of the effectiveness of 3,000 to 4,000 drugs introduced between 1938-1962 under a $834,000 contract from the Food and Drug Administration. In October 1964 the Drug Research Board passed a resolution approving in principle the idea of a complimentary drug compendium to replace package inserts. However, the Academy-Research Council traditionally does not undertake operational programs of a continuing nature and thus its role in the Drug Compendium has been one of helping to find an organization to undertake the project on a lasting basis.
The Drug Compendium has the active support of F.D.A. Commissioner James L. Goddard who has agreed to relieve pharmaceutical manufacturers of the necessity to furnish package inserts when the compendium is published. The physician now normally does not see the package insert and, therefore, cannot benefit from its contents unless he calls the pharmacist.
Approximately 600,000 copies of the book will be distributed free and it is possible that an equal number will be sold. Revisions and material on new drugs will be issued every two to three months, and a new edition of the compendium will be published annually.
Responsibility for the Drug Compendium will be assigned to professional groups with experience in compiling drug compendia, such as those preparing the United States Pharmacopeia and National Formulary. An organization similar to that of the Drug Efficacy Study 1 which has a Policy Advisory Committee of outstanding physicians and twenty-seven panels of speialists in different areas of clinical practice will be established to write the material to be include in the compendium. Much of this material for drugs released between 1938-1962 has already been written by the Drug Efficacy Study panels and is essentially ready for publication. The new organization for the Drug Compendium will undertake preparation of therapeutic information on all post-1962 drugs and will consider the problems posed by drugs released prior to 1938 and those that are now exempt by the Food and Drug Administration from the package insert requirement.
Only one description of the therapeutic uses will be written for single entities of identical composition such as meprobamate. Proprietary as well as non-proprietary names will undoubtedly be included. Firms producing the drug will be listed and specific claims that a firm can cite will be included, provided that they are supported by clinical studies. So called "generic equivalents" may be required to show proof of efficacy with animal or clinical studies or carry a statement that no controlled efficacy studies have been made.
AN AMERICAN DRUG COMPENDIUM
The organizational plan to produce the Drug Compendium will be somewhat as follows. The Food and Drug Administration will enter into a contract with the professional organization ( s) to produce the revised package inserts, utilizing-outside consultants as required. Thus, F.D.A. will finance the compilation of the compendium. At this point, pharmaceutical manufacturers, such as the Pharmaceutical Manufacturers Associatipn and possihly others, will be asked to support the actual printing and distribution of the compendium. The drug industry has previously reported that it costs about $6 million a year to furnish package inserts, and these costs will be largely eliminated if package inserts are no longer required. It is possible that the Drug Compendium could be essentially self-supporting if projections of possible sales are correct.
The professional organization ( s) selected to compile the compendium will work closely with the pharmaceutical industry, but the final copy will be reviewed and approved by the Food and Drug Administration . . A master stroke was dealt by F.D.A. Commissioner Goddard when he conceived the idea of enlisting the aid of the Drug Research Board NAS-NRC to conduct drug efficacy studies on drugs released between . The key to the success of this endeavor is the creation of the specialty panels composed of outstanding clinicians to revise the package inserts and to comment on the claims made therein. This has had the effect of removing from the F.D.A. the onus of being accused of being arbitrary or capricious in the claims and statements it permits pharmaceutical companies to make in their package brochures. Now, eminent clinical practitioner~ and professors review and· comment on the package inserts and thus relieve F.D.A. of much of the burden previously borne. When the best medical opinion in the country does not approve of a claim made in the package insert, it is accepted much more gracefully by the pharmaceutical company than if a F.D.A. physician alone did not approve it.
The revised inserts will represent che best medical opinon in the country and should do much to raise the general level of clinical practice as it relates to the use of drugs. It should also contribute greatly to the work of pharmacy and therapeutic committees throughout the country by providing unquestionable authoritative opinion and guidance on , the rationale uses of drugs in therapy. Appearance of the new Drug Compendium will be welcomed by all health practitioners.
